G
Gregory P. Kalemkerian
Researcher at University of Michigan
Publications - 147
Citations - 7011
Gregory P. Kalemkerian is an academic researcher from University of Michigan. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 35, co-authored 135 publications receiving 5692 citations. Previous affiliations of Gregory P. Kalemkerian include University of New Mexico.
Papers
More filters
Journal ArticleDOI
High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non–small-cell lung cancer: Long-term results of a radiation dose escalation study
Feng Ming Kong,Randall K. Ten Haken,Matthew J. Schipper,Molly A. Sullivan,Ming Chen,Carlos López,Gregory P. Kalemkerian,James A. Hayman +7 more
TL;DR: Higher dose radiation is associated with improved outcomes in patients with NSCLC treated in the range of 63-103 Gy, and presence of nodal disease was negatively associated with locoregional control under univariate analysis.
Journal ArticleDOI
Small cell lung cancer.
Gregory P. Kalemkerian,Wallace Akerley,Robert J. Downey,David S. Ettinger,Frank V. Fossella,John C. Grecula,Thierry Jahan,Bruce E. Johnson,Anne Kessinger,Marianna Koczywas,Corey J. Langer,Renato G. Martins,Harvey B. Niell,Charles C. Pan,Nithya Ramnath,Neal Ready,Francisco Robert,Charles C. Williams +17 more
TL;DR: In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare, and smoking cessation should be strongly promoted.
Journal ArticleDOI
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
Gregory P. Kalemkerian,Navneet Narula,Erin B. Kennedy,William A. Biermann,Jessica S. Donington,Natasha B. Leighl,Madelyn Lew,James Pantelas,Suresh S. Ramalingam,Martin Reck,Anjali Saqi,Michael Simoff,Navneet Singh,Navneet Singh,Baskaran Sundaram +14 more
TL;DR: This update clarifies that any sample with adequate cellularity and preservation may be tested and that analytical methods must be able to detect mutation in a sample with as little as 20% cancer cells and strongly recommends against evaluating epidermal growth factor receptor expression by immunohistochemistry for selection of patients for EGFR-targeted therapy.
Journal ArticleDOI
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Charles M. Rudin,Mark M. Awad,Alejandro Navarro,Maya Gottfried,Solange Peters,Tibor Csőszi,Parneet Cheema,Delvys Rodriguez-Abreu,Mirjana Wollner,James Chih-Hsin Yang,Julien Mazieres,Francisco Orlandi,Alexander Luft,Mahmut Gumus,Terufumi Kato,Gregory P. Kalemkerian,Yiwen Luo,Victoria Ebiana,M. Catherine Pietanza,Hye Ryun Kim,Keynote Investigators +20 more
TL;DR: Pembrolizumab plus EP significantly improved progression-free survival (PFS) and overall survival (OS) compared with placebo plus EP as first-line therapy for patients with ES-SCLC, and these data support the benefit of pembrolIZumab in ES-sCLC.
Journal ArticleDOI
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
Feng Ming Kong,Feng Ming Kong,James A. Hayman,Kent A. Griffith,Gregory P. Kalemkerian,Douglas A. Arenberg,Susan E. Lyons,Andrew T. Turrisi,Allen S. Lichter,Benedick A. Fraass,Avraham Eisbruch,Theodore S. Lawrence,Randall K. Ten Haken +12 more
TL;DR: With long-term follow-up for toxicity, it is demonstrated that much higher doses of radiation than are traditionally administered can be safely delivered to a majority of patients with NSCLC.